| HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2054 | Lisocabtagene maraleucel | Breyanzi | Immunotherapy | CAR-T | CD19 | No | 2021 | Sep 27, 2021 | In Use | |||
| NA | Gardasil | Human papillomavirus vaccine | Ancillary Therapy | Protective Agent | HPV Vaccine | No | 2006 | 2016 | In Use | |||
| C9076 | Lisocabtagene maraleucel | Breyanzi | Immunotherapy | CAR-T | CD19 | No | 2021 | Jul 23, 2021 | Sep 27, 2021 | No Longer Used | ||
| NA | Bromocriptine Mesylate | Parlodel | Chemotherapy | Dopamine Agonist | Ergot Derivative | Yes | 1978 | In Use | ||||
| NA | Gardasil-9 | Human papillomavirus vaccine | Ancillary Therapy | Protective Agent | HPV Vaccine | No | 2016 | In Use | ||||
| C9297 | Omacetaxine | Synribo | 0.01 mg | Chemotherapy | Plant Alkaloid | BCR-ABL | No | 2012 | Apr 1, 2013 | Dec 31, 2013 | No Longer Used | |
| J9262 | Omacetaxine | Synribo | 0.01 mg | Chemotherapy | Plant Alkaloid | BCR-ABL | No | 2012 | Jan 1, 2014 | In Use | ||
| NA | Bexarotene | Targretin | 0.01 | Chemotherapy | Immunomodulator | Retinoic Acid Derivative | No | 2014 | In Use | |||
| J9313 | Moxetumomab-pasudotox-tdfk | Lumoxiti | 0.01mg | Immunotherapy | Drug Antibody Conjugate | CD22 | No | 2018 | Oct 1, 2019 | In Use | ||
| J9359 | Loncastuximab tesirine-lpyl | Zynlonta | 0.075mg | Immunotherapy | Drug Antibody Conjugate | CD19 | No | 2021 | Mar 25, 2022 | In Use | ||
| J9203 | Gemtuzumab ozogamicin | Mylotarg | 0.1 mg | Immunotherapy | Drug Antibody Conjugate | CD33 | No | 2000 | Jan 1, 2018 | In Use | ||
| J1627 | Granisetron Hydrochloride Extended Release | Granisol [DSC], Sancuso, Sustol, Kytril | 0.1 mg | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | No | 2016 | Jan 1, 2018 | In Use | ||
| J9041 | Bortezomib | Velcade | 0.1 mg | Chemotherapy | Proteasome Inhibitor | 26S | No | 2003 | Jan 1, 2005 | In Use | ||
| C9480 | Trabectedin | Yondelis | 0.1 mg | Chemotherapy | Alkylating Agent | Natural Product | No | 2015 | Jul 1, 2016 | In Use | ||
| J9351 | Topotecan | Hycamtin | 0.1 mg | Chemotherapy | Topoisomerase I Inhibitor | Campothecin Analogs | No | 1996 | Jan 1, 2011 | In Use | ||
| J9179 | Eribulin mesylate | Halaven | 0.1 mg | Chemotherapy | Antimitotic Agent | Furopyrans | No | 2010 | Jan 1, 2012 | In Use | ||
| NA | Alitretinoin | Panretin | 0.10% | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | No | 1999 | In Use | |||
| C9155 | Epcoritamab-bysp | Epkinly | 0.16mg | Immunotherapy | Monoclonal Antibody | CD20, CD3 | No | 2023 | Aug 28, 2023 | Dec 7, 2023 | No Longer Used | |
| J9321 | Epcoritamab-bysp | Epkinly | 0.16mg | Immunotherapy | Monoclonal Antibody | CD20, CD3 | No | 2023 | Dec 7, 2023 | In Use | ||
| J9223 | Lurbinectedin | Zepzelca | 0.1mg | Chemotherapy | Alkylating Agent | Adduct Forming Agent | No | 2020 | Jan 1, 2021 | In Use | ||
| J9048 | Bortezomib (Fresniuskab) | Bortezomib (Fresniuskab) | 0.1mg | Chemotherapy | Proteasome Inhibitor | 26S | No | 2017 | Dec 21, 2022 | In Use | ||
| J9046 | Bortezomib (Dr Reddy) | Bortezomib (Dr Reddy) | 0.1mg | Chemotherapy | Proteasome Inhibitor | 26S | No | 2022 | Dec 21, 2022 | In Use | ||
| C9084 | Loncastuximab tesirine | Zylonta | 0.1mg | Immunotherapy | Drug Antibody Conjugate | CD19 | No | 2021 | Sep 27, 2021 | Mar 25, 2022 | In Use | |
| J9352 | Trabectedin | Yondelis | 0.1mg | Chemotherapy | Alkylating Agent | Natural Product | No | 2015 | Jan 1, 2017 | In Use | ||
| J9021 | Asparaginase Erwinia Chrysanthemi (recombinant)-rywn | Rylaze | 0.1mg | Chemotherapy | Miscellaneous Agent | Enzyme | No | 2021 | Jan 26, 2022 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.
Home